Digital Cognitive Behavioral Therapy for Insomnia in Women With Chronic Migraines

Objective/Background: Insomnia commonly co-occurs with chronic migraines (CM). Non-pharmacological treatments for insomnia in CM patients remain understudied. This is a proof-of-concept study, which aims to evaluate the feasibility, acceptability, and preliminary efficacy of a digital cognitive behavioral therapy for insomnia (dCBT-I) for individuals with CM and insomnia (CM-I) in the United States. Methods: We recruited 42 females with CM-I symptoms from a U.S.-based observational cohort and from the general population via advertisements. Within a multiple baseline design, participants were randomized to receive dCBT-I after 2, 4, or 6 weeks of completing baseline sleep diaries. DCBT-I was scrutinized against benchmarks for completion rates (≥90% to complete dCBT-I), acceptability (≥80% to find dCBT-I acceptable), and posttreatment changes in insomnia symptoms (≥50% indicating a clinically relevant improvement in their insomnia symptoms). As a secondary measure, we also reported percentage of individuals reverting to episodic migraines. Results: Out of 42 randomized, 35 (83.3%) completed dCBT-I within the 12 weeks provided. Of these completers, 33 (94.3%) reported being satisfied (n = 16) or very satisfied (n = 17) with treatment. Additionally, 65.7% of completers responded to treatment as per universally accepted criteria for insomnia. Lastly, 34% of completers reverted from CM to episodic migraine. Conclusion: This study provides evidence for the feasibility and acceptability of dCBT-I in patients with CM-I complaints. Effects of improving insomnia and migraines were suggested. These results indicate that a randomized controlled trial is needed to determine the efficacy of dCBT-I in CM patients

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

BACKGROUND: Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 vaccination was introduced. METHODS: In this follow up study, plasma and nasosorption samples were prospectively collected from 446 adults hospitalised for COVID-19 between February 2020 and March 2021 via the ISARIC4C and PHOSP-COVID consortia. IgA and IgG responses to NP and S of ancestral SARS-CoV-2, Delta and Omicron (BA.1) variants were measured by electrochemiluminescence and compared with plasma neutralisation data. FINDINGS: Strong and consistent nasal anti-NP and anti-S IgA responses were demonstrated, which remained elevated for nine months (p < 0.0001). Nasal and plasma anti-S IgG remained elevated for at least 12 months (p < 0.0001) with plasma neutralising titres that were raised against all variants compared to controls (p < 0.0001). Of 323 with complete data, 307 were vaccinated between 6 and 12 months; coinciding with rises in nasal and plasma IgA and IgG anti-S titres for all SARS-CoV-2 variants, although the change in nasal IgA was minimal (1.46-fold change after 10 months, p = 0.011) and the median remained below the positive threshold determined by pre-pandemic controls. Samples 12 months after admission showed no association between nasal IgA and plasma IgG anti-S responses (R = 0.05, p = 0.18), indicating that nasal IgA responses are distinct from those in plasma and minimally boosted by vaccination. INTERPRETATION: The decline in nasal IgA responses 9 months after infection and minimal impact of subsequent vaccination may explain the lack of long-lasting nasal defence against reinfection and the limited effects of vaccination on transmission. These findings highlight the need to develop vaccines that enhance nasal immunity. FUNDING: This study has been supported by ISARIC4C and PHOSP-COVID consortia. ISARIC4C is supported by grants from the National Institute for Health and Care Research and the Medical Research Council. Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research. The PHOSP-COVD study is jointly funded by UK Research and Innovation and National Institute of Health and Care Research. The funders were not involved in the study design, interpretation of data or the writing of this manuscript

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

One in ten severe acute respiratory syndrome coronavirus 2 infections result in prolonged symptoms termed long coronavirus disease (COVID), yet disease phenotypes and mechanisms are poorly understood1. Here we profiled 368 plasma proteins in 657 participants ≥3 months following hospitalization. Of these, 426 had at least one long COVID symptom and 233 had fully recovered. Elevated markers of myeloid inflammation and complement activation were associated with long COVID. IL-1R2, MATN2 and COLEC12 were associated with cardiorespiratory symptoms, fatigue and anxiety/depression; MATN2, CSF3 and C1QA were elevated in gastrointestinal symptoms and C1QA was elevated in cognitive impairment. Additional markers of alterations in nerve tissue repair (SPON-1 and NFASC) were elevated in those with cognitive impairment and SCG3, suggestive of brain–gut axis disturbance, was elevated in gastrointestinal symptoms. Severe acute respiratory syndrome coronavirus 2-specific immunoglobulin G (IgG) was persistently elevated in some individuals with long COVID, but virus was not detected in sputum. Analysis of inflammatory markers in nasal fluids showed no association with symptoms. Our study aimed to understand inflammatory processes that underlie long COVID and was not designed for biomarker discovery. Our findings suggest that specific inflammatory pathways related to tissue damage are implicated in subtypes of long COVID, which might be targeted in future therapeutic trials

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

Background The impact of COVID-19 on physical and mental health and employment after hospitalisation with acute disease is not well understood. The aim of this study was to determine the effects of COVID-19-related hospitalisation on health and employment, to identify factors associated with recovery, and to describe recovery phenotypes. Methods The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a multicentre, long-term follow-up study of adults (aged ≥18 years) discharged from hospital in the UK with a clinical diagnosis of COVID-19, involving an assessment between 2 and 7 months after discharge, including detailed recording of symptoms, and physiological and biochemical testing. Multivariable logistic regression was done for the primary outcome of patient-perceived recovery, with age, sex, ethnicity, body-mass index, comorbidities, and severity of acute illness as covariates. A post-hoc cluster analysis of outcomes for breathlessness, fatigue, mental health, cognitive impairment, and physical performance was done using the clustering large applications k-medoids approach. The study is registered on the ISRCTN Registry (ISRCTN10980107). Findings We report findings for 1077 patients discharged from hospital between March 5 and Nov 30, 2020, who underwent assessment at a median of 5·9 months (IQR 4·9–6·5) after discharge. Participants had a mean age of 58 years (SD 13); 384 (36%) were female, 710 (69%) were of white ethnicity, 288 (27%) had received mechanical ventilation, and 540 (50%) had at least two comorbidities. At follow-up, only 239 (29%) of 830 participants felt fully recovered, 158 (20%) of 806 had a new disability (assessed by the Washington Group Short Set on Functioning), and 124 (19%) of 641 experienced a health-related change in occupation. Factors associated with not recovering were female sex, middle age (40–59 years), two or more comorbidities, and more severe acute illness. The magnitude of the persistent health burden was substantial but only weakly associated with the severity of acute illness. Four clusters were identified with different severities of mental and physical health impairment (n=767): very severe (131 patients, 17%), severe (159, 21%), moderate along with cognitive impairment (127, 17%), and mild (350, 46%). Of the outcomes used in the cluster analysis, all were closely related except for cognitive impairment. Three (3%) of 113 patients in the very severe cluster, nine (7%) of 129 in the severe cluster, 36 (36%) of 99 in the moderate cluster, and 114 (43%) of 267 in the mild cluster reported feeling fully recovered. Persistently elevated serum C-reactive protein was positively associated with cluster severity. Interpretation We identified factors related to not recovering after hospital admission with COVID-19 at 6 months after discharge (eg, female sex, middle age, two or more comorbidities, and more acute severe illness), and four different recovery phenotypes. The severity of physical and mental health impairments were closely related, whereas cognitive health impairments were independent. In clinical care, a proactive approach is needed across the acute severity spectrum, with interdisciplinary working, wide access to COVID-19 holistic clinical services, and the potential to stratify care. Funding UK Research and Innovation and National Institute for Health Research

Ultracool dwarfs in Gaia DR3

Context: Previous Gaia data releases offered the opportunity to uncover ultracool dwarfs (UCDs) through astrometric, rather than purely photometric, selection. The most recent, the third data release (DR3), offers in addition the opportunity to use low-resolution spectra to refine and widen the selection. Aims. In this work we use the Gaia DR3 set of UCD candidates and complement the Gaia spectrophotometry with additional photometry in order to characterise the global properties of the set. This includes the inference of the distances, their locus in the Gaia colour-absolute magnitude diagram, and the (biased through selection) luminosity function at the faint end of the main sequence. We study the overall changes in the Gaia RP spectra as a function of spectral type. We study the UCDs in binary systems, we attempt to identify low-mass members of nearby young associations, star-forming regions, and clusters, and we analyse their variability properties. Methods: We used a forward model and the Bayesian inference framework to produce posterior probabilities for the distribution parameters and a calibration of the colour index as a function of the absolute magnitude in the form of a Gaussian process. Additionally, we applied the hierarchical mode association clustering (HMAC) unsupervised classification algorithm for the detection and characterisation of overdensities in the space of celestial coordinates, projected velocities, and parallaxes. Results: We detect 57 young, kinematically homogeneous groups, some of which are identified as well-known star-forming regions, associations, and clusters of different ages. We find that the primary members of the 880 binary systems with a UCD belong to the thin and thick disc components of the Milky Way. We identify 1109 variable UCDs using the variability tables in the Gaia archive, 728 of which belong to the star-forming regions defined by HMAC. We define two groups of variable UCDs with extreme bright or faint outliers. Conclusions: The set of sources identified as UCDs in the Gaia archive contains a wealth of information that will require focused follow-up studies and observations. It will help advance our understanding of the nature of the faint end of the main sequence and the stellar-substellar transition.This work has made use of results from the European Space Agency (ESA) space mission Gaia, the data from which were processed by the Gaia Data Processing and Analysis Consortium (DPAC). The Gaia mission website is http://www.cosmos.esa.int/gaia. This work was supported by the MCIN (Spanish Ministry of Science and Innovation) through grant PID2020-112949GB-I00; the MINECO (Spanish Ministry of Economy) through grants AyA2017-84089, ESP2016-80079-C2-1-R, ESP2014-55996-C2-1-R, and RTI2018-095076-B-C22 (MINECO/FEDER, UE). This research has been funded by the Spanish State Research Agency (AEI) Projects No.PID2019-107061GB-C61 and No. MDM-2017-0737 Unidad de Excelencia “María de Maeztu”- Centro de Astrobiología (CSIC/INTA). Ground based spectra is from observations made with the Gran Telescopio Canarias (GTC), installed in the Spanish Observatorio del Roque de los Muchachos of the Instituto de Astrofísica de Canarias, on the island of La Palma. The GTC data was obtained with the instrument OSIRIS, built by a Consortium led by the Instituto de Astrofísica de Canarias in collaboration with the Instituto de Astronomía of the Universidad Autónoma de México. OSIRIS was funded by GRANTECAN and the National Plan of Astronomy and Astrophysics of the Spanish Government. The programme codes were GTC54-15A0 & GTC8-15ITP. This work has made use of the Python package GaiaXPy, developed and maintained by members of the Gaia Data Processing and Analysis Consortium (DPAC), and in particular, Coordination Unit 5 (CU5), and the Data Processing Centre located at the Institute of Astronomy, Cambridge, UK (DPCI). We derived extiction corrections using the Python package dustmap (Green 2018)

Gaia Data Release 3: astrophysical parameters inference system (Apsis). I. Methods and content overview

Gaia Data Release 3 contains a wealth of new data products for the community. Astrophysical parameters are a major component of this release, and were produced by the Astrophysical parameters inference system (Apsis) within the Gaia Data Processing and Analysis Consortium (DPAC). The aim of this paper is to describe the overall content of the astrophysical parameters in Gaia DR3 and how they were produced. In Apsis, we use the mean BP/RP and mean RVS spectra along with astrometry and photometry, and we derive the following parameters: source classification and probabilities for 1.6 billion objects; interstellar medium characterisation and distances for up to 470 million sources, including a 2D total Galactic extinction map; 6 million redshifts of quasar candidates; 1.4 million redshifts of galaxy candidates; and an analysis of 50 million outlier sources through an unsupervised classification. The astrophysical parameters also include many stellar spectroscopic and evolutionary parameters for up to 470 million sources. These comprise Teff, log g, and [M/H] (470 million using BP/RP, 6 million using RVS), radius (470 million), mass (140 million), age (120 million), chemical abundances (up to 5 million), diffuse interstellar band analysis (0.5 million), activity indices (2 million), Hα equivalent widths (200 million), and further classification of spectral types (220 million) and emission-line stars (50 000). This paper is the first in a series of three papers, and focusses on describing the global content of the parameters in Gaia DR3. The accompanying Papers II and III focus on the validation and use of the stellar and non-stellar products, respectively. This catalogue is the most extensive homogeneous database of astrophysical parameters to date, and is based uniquely on Gaia data. It will only be superseded by Gaia Data Release 4, and will therefore remain a key reference over the next four years, providing astrophysical parameters independent of other ground- and space-based data.The Gaia mission and data processing have financially been supported by, in alphabetical order by country: – the Algerian Centre de Recherche en Astronomie, Astrophysique et Géophysique of Bouzareah Observatory; – the Austrian Fonds zur Förderung der wissenschaftlichen Forschung (FWF) Hertha Firnberg Programme through grants T359, P20046, and P23737; – the BELgian federal Science Policy Office (BELSPO) through various PROgramme de Développement d’Expériences scientifiques (PRODEX) grants, the Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek) through grant VS.091.16N, the Fonds de la Recherche Scientifique (FNRS), and the Research Council of Katholieke Universiteit (KU) Leuven through grant C16/18/005 (Pushing AsteRoseismology to the next level with TESS, GaiA, and the Sloan DIgital Sky SurvEy – PARADISE); – the Brazil-France exchange programmes Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Coordenação de Aperfeicoamento de Pessoal de Nível Superior (CAPES) - Comité Français d’Evaluation de la Coopération Universitaire et Scientifique avec le Brésil (COFECUB); – the Chilean Agencia Nacional de Investigación y Desarrollo (ANID) through Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) Regular Project 1210992 (L. Chemin); – the National Natural Science Foundation of China (NSFC) through grants 11573054, 11703065, and 12173069, the China Scholarship Council through grant 201806040200, and the Natural Science Foundation of Shanghai through grant 21ZR1474100; – the Tenure Track Pilot Programme of the Croatian Science Foundation and the École Polytechnique Fédérale de Lausanne and the project TTP-2018-07-1171 ‘Mining the Variable Sky’, with the funds of the Croatian-Swiss Research Programme; – the Czech-Republic Ministry of Education, Youth, and Sports through grant LG 15010 and INTER-EXCELLENCE grant LTAUSA18093, and the Czech Space Office through ESA PECS contract 98058; – the Danish Ministry of Science; – the Estonian Ministry of Education and Research through grant IUT40-1; – the European Commission’s Sixth Framework Programme through the European Leadership in Space Astrometry (ELSA) Marie Curie Research Training Network (MRTN-CT-2006-033481), through Marie Curie project PIOF-GA-2009-255267 (Space AsteroSeismology & RR Lyrae stars, SAS-RRL), and through a Marie Curie Transfer-of-Knowledge (ToK) fellowship (MTKD-CT-2004-014188); the European Commission’s Seventh Framework Programme through grant FP7-606740 (FP7-SPACE-2013-1) for the Gaia European Network for Improved data User Services (GENIUS) and through grant 264895 for the Gaia Research for European Astronomy Training (GREAT-ITN) network; – the European Cooperation in Science and Technology (COST) through COST Action CA18104 ‘Revealing the Milky Way with Gaia(MW-Gaia)’; – the European Research Council (ERC) through grants 320360, 647208, and 834148 and through the European Union’s Horizon 2020 research and innovation and excellent science programmes through Marie Skłodowska-Curie grant 745617 (Our Galaxy at full HD – Gal-HD) and 895174 (The build-up and fate of self-gravitating systems in the Universe) as well as grants 687378 (Small Bodies: Near and Far), 682115 (Using the Magellanic Clouds to Understand the Interaction of Galaxies), 695099 (A sub-percent distance scale from binaries and Cepheids – CepBin), 716155 (Structured ACCREtion Disks – SACCRED), 951549 (Sub-percent calibration of the extragalactic distance scale in the era of big surveys – UniverScale), and 101004214 (Innovative Scientific Data Exploration and Exploitation Applications for Space Sciences – EXPLORE); – the European Science Foundation (ESF), in the framework of the Gaia Research for European Astronomy Training Research Network Programme (GREAT-ESF); – the European Space Agency (ESA) in the framework of the Gaia project, through the Plan for European Cooperating States (PECS) programme through contracts C98090 and 4000106398/12/NL/KML for Hungary, through contract 4000115263/15/NL/IB for Germany, and through PROgramme de Développement d’Expériences scientifiques (PRODEX) grant 4000127986 for Slovenia; – the Academy of Finland through grants 299543, 307157, 325805, 328654, 336546, and 345115 and the Magnus Ehrnrooth Foundation; – the French Centre National d’Études Spatiales (CNES), the Agence Nationale de la Recherche (ANR) through grant ANR-10-IDEX-0001-02 for the ‘Investissements d’avenir’ programme, through grant ANR-15-CE31-0007 for project ‘Modelling the Milky Way in the Gaiaera’ (MOD4Gaia), through grant ANR-14-CE33-0014-01 for project ‘The Milky Way disc formation in the Gaiaera’ (ARCHEOGAL), through grant ANR-15-CE31-0012-01 for project ‘Unlocking the potential of Cepheids as primary distance calibrators’ (UnlockCepheids), through grant ANR-19-CE31-0017 for project ‘Secular evolution of galxies’ (SEGAL), and through grant ANR-18-CE31-0006 for project ‘Galactic Dark Matter’ (GaDaMa), the Centre National de la Recherche Scientifique (CNRS) and its SNO Gaiaof the Institut des Sciences de l’Univers (INSU), its Programmes Nationaux: Cosmologie et Galaxies (PNCG), Gravitation Références Astronomie Métrologie (PNGRAM), Planétologie (PNP), Physique et Chimie du Milieu Interstellaire (PCMI), and Physique Stellaire (PNPS), the ‘Action Fédératrice Gaia’ of the Observatoire de Paris, the Région de Franche-Comté, the Institut National Polytechnique (INP) and the Institut National de Physique nucléaire et de Physique des Particules (IN2P3) co-funded by CNES; – the German Aerospace Agency (Deutsches Zentrum für Luft- und Raumfahrt e.V., DLR) through grants 50QG0501, 50QG0601, 50QG0602, 50QG0701, 50QG0901, 50QG1001, 50QG1101, 50QG1401, 50QG1402, 50QG1403, 50QG1404, 50QG1904, 50QG2101, 50QG2102, and 50QG2202, and the Centre for Information Services and High Performance Computing (ZIH) at the Technische Universität Dresden for generous allocations of computer time; – the Hungarian Academy of Sciences through the Lendület Programme grants LP2014-17 and LP2018-7 and the Hungarian National Research, Development, and Innovation Office (NKFIH) through grant KKP-137523 (‘SeismoLab’); – the Science Foundation Ireland (SFI) through a Royal Society - SFI University Research Fellowship (M. Fraser); – the Israel Ministry of Science and Technology through grant 3-18143 and the Tel Aviv University Center for Artificial Intelligence and Data Science (TAD) through a grant; – the Agenzia Spaziale Italiana (ASI) through contracts I/037/08/0, I/058/10/0, 2014-025-R.0, 2014-025-R.1.2015, and 2018-24-HH.0 to the Italian Istituto Nazionale di Astrofisica (INAF), contract 2014-049-R.0/1/2 to INAF for the Space Science Data Centre (SSDC, formerly known as the ASI Science Data Center, ASDC), contracts I/008/10/0, 2013/030/I.0, 2013-030-I.0.1-2015, and 2016-17-I.0 to the Aerospace Logistics Technology Engineering Company (ALTEC S.p.A.), INAF, and the Italian Ministry of Education, University, and Research (Ministero dell’Istruzione, dell’Università e della Ricerca) through the Premiale project ‘MIning The Cosmos Big Data and Innovative Italian Technology for Frontier Astrophysics and Cosmology’ (MITiC); – the Netherlands Organisation for Scientific Research (NWO) through grant NWO-M-614.061.414, through a VICI grant (A. Helmi), and through a Spinoza prize (A. Helmi), and the Netherlands Research School for Astronomy (NOVA); – the Polish National Science Centre through HARMONIA grant 2018/30/M/ST9/00311 and DAINA grant 2017/27/L/ST9/03221 and the Ministry of Science and Higher Education (MNiSW) through grant DIR/WK/2018/12; – the Portuguese Fundação para a Ciência e a Tecnologia (FCT) through national funds, grants SFRH/BD/128840/2017 and PTDC/FIS-AST/30389/2017, and work contract DL 57/2016/CP1364/CT0006, the Fundo Europeu de Desenvolvimento Regional (FEDER) through grant POCI-01-0145-FEDER-030389 and its Programa Operacional Competitividade e Internacionalização (COMPETE2020) through grants UIDB/04434/2020 and UIDP/04434/2020, and the Strategic Programme UIDB/00099/2020 for the Centro de Astrofísica e Gravitação (CENTRA); – the Slovenian Research Agency through grant P1-0188; – the Spanish Ministry of Economy (MINECO/FEDER, UE), the Spanish Ministry of Science and Innovation (MICIN), the Spanish Ministry of Education, Culture, and Sports, and the Spanish Government through grants BES-2016-078499, BES-2017-083126, BES-C-2017-0085, ESP2016-80079-C2-1-R, ESP2016-80079-C2-2-R, FPU16/03827, PDC2021-121059-C22, RTI2018-095076-B-C22, and TIN2015-65316-P (‘Computación de Altas Prestaciones VII’), the Juan de la Cierva Incorporación Programme (FJCI-2015-2671 and IJC2019-04862-I for F. Anders), the Severo Ochoa Centre of Excellence Programme (SEV2015-0493), and MICIN/AEI/10.13039/501100011033 (and the European Union through European Regional Development Fund ‘A way of making Europe’) through grant RTI2018-095076-B-C21, the Institute of Cosmos Sciences University of Barcelona (ICCUB, Unidad de Excelencia ‘María de Maeztu’) through grant CEX2019-000918-M, the University of Barcelona’s official doctoral programme for the development of an R+D+i project through an Ajuts de Personal Investigador en Formació (APIF) grant, the Spanish Virtual Observatory through project AyA2017-84089, the Galician Regional Government, Xunta de Galicia, through grants ED431B-2021/36, ED481A-2019/155, and ED481A-2021/296, the Centro de Investigación en Tecnologías de la Información y las Comunicaciones (CITIC), funded by the Xunta de Galicia and the European Union (European Regional Development Fund – Galicia 2014-2020 Programme), through grant ED431G-2019/01, the Red Española de Supercomputación (RES) computer resources at MareNostrum, the Barcelona Supercomputing Centre - Centro Nacional de Supercomputación (BSC-CNS) through activities AECT-2017-2-0002, AECT-2017-3-0006, AECT-2018-1-0017, AECT-2018-2-0013, AECT-2018-3-0011, AECT-2019-1-0010, AECT-2019-2-0014, AECT-2019-3-0003, AECT-2020-1-0004, and DATA-2020-1-0010, the Departament d’Innovació, Universitats i Empresa de la Generalitat de Catalunya through grant 2014-SGR-1051 for project ‘Models de Programació i Entorns d’Execució Parallels’ (MPEXPAR), and Ramon y Cajal Fellowship RYC2018-025968-I funded by MICIN/AEI/10.13039/501100011033 and the European Science Foundation (‘Investing in your future’); – the Swedish National Space Agency (SNSA/Rymdstyrelsen); – the Swiss State Secretariat for Education, Research, and Innovation through the Swiss Activités Nationales Complémentaires and the Swiss National Science Foundation through an Eccellenza Professorial Fellowship (award PCEFP2_194638 for R. Anderson); – the United Kingdom Particle Physics and Astronomy Research Council (PPARC), the United Kingdom Science and Technology Facilities Council (STFC), and the United Kingdom Space Agency (UKSA) through the following grants to the University of Bristol, the University of Cambridge, the University of Edinburgh, the University of Leicester, the Mullard Space Sciences Laboratory of University College London, and the United Kingdom Rutherford Appleton Laboratory (RAL): PP/D006511/1, PP/D006546/1, PP/D006570/1, ST/I000852/1, ST/J005045/1, ST/K00056X/1, ST/K000209/1, ST/K000756/1, ST/L006561/1, ST/N000595/1, ST/N000641/1, ST/N000978/1, ST/N001117/1, ST/S000089/1, ST/S000976/1, ST/S000984/1, ST/S001123/1, ST/S001948/1, ST/S001980/1, ST/S002103/1, ST/V000969/1, ST/W002469/1, ST/W002493/1, ST/W002671/1, ST/W002809/1, and EP/V520342/1. The GBOT programme uses observations collected at (i) the European Organisation for Astronomical Research in the Southern Hemisphere (ESO) with the VLT Survey Telescope (VST), under ESO programmes 092.B-0165, 093.B-0236, 094.B-0181, 095.B-0046, 096.B-0162, 097.B-0304, 098.B-0030, 099.B-0034, 0100.B-0131, 0101.B-0156, 0102.B-0174, and 0103.B-0165; and (ii) the Liverpool Telescope, which is operated on the island of La Palma by Liverpool John Moores University in the Spanish Observatorio del Roque de los Muchachos of the Instituto de Astrofísica de Canarias with financial support from the United Kingdom Science and Technology Facilities Council, and (iii) telescopes of the Las Cumbres Observatory Global Telescope Network

Termite sensitivity to temperature affects global wood decay rates

Deadwood is a large global carbon store with its store size partially determined by biotic decay. Microbial wood decay rates are known to respond to changing temperature and precipitation. Termites are also important decomposers in the tropics but are less well studied. An understanding of their climate sensitivities is needed to estimate climate change effects on wood carbon pools. Using data from 133 sites spanning six continents, we found that termite wood discovery and consumption were highly sensitive to temperature (with decay increasing &gt;6.8 times per 10°C increase in temperature)—even more so than microbes. Termite decay effects were greatest in tropical seasonal forests, tropical savannas, and subtropical deserts. With tropicalization (i.e., warming shifts to tropical climates), termite wood decay will likely increase as termites access more of Earth’s surface.</p

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyResearch in context

Summary: Background: The scale of COVID-19 and its well documented long-term sequelae support a need to understand long-term outcomes including frailty. Methods: This prospective cohort study recruited adults who had survived hospitalisation with clinically diagnosed COVID-19 across 35 sites in the UK (PHOSP-COVID). The burden of frailty was objectively measured using Fried's Frailty Phenotype (FFP). The primary outcome was the prevalence of each FFP group—robust (no FFP criteria), pre-frail (one or two FFP criteria) and frail (three or more FFP criteria)—at 5 months and 1 year after discharge from hospital. For inclusion in the primary analysis, participants required complete outcome data for three of the five FFP criteria. Longitudinal changes across frailty domains are reported at 5 months and 1 year post-hospitalisation, along with risk factors for frailty status. Patient-perceived recovery and health-related quality of life (HRQoL) were retrospectively rated for pre-COVID-19 and prospectively rated at the 5 month and 1 year visits. This study is registered with ISRCTN, number ISRCTN10980107. Findings: Between March 5, 2020, and March 31, 2021, 2419 participants were enrolled with FFP data. Mean age was 57.9 (SD 12.6) years, 933 (38.6%) were female, and 429 (17.7%) had received invasive mechanical ventilation. 1785 had measures at both timepoints, of which 240 (13.4%), 1138 (63.8%) and 407 (22.8%) were frail, pre-frail and robust, respectively, at 5 months compared with 123 (6.9%), 1046 (58.6%) and 616 (34.5%) at 1 year. Factors associated with pre-frailty or frailty were invasive mechanical ventilation, older age, female sex, and greater social deprivation. Frail participants had a larger reduction in HRQoL compared with before their COVID-19 illness and were less likely to describe themselves as recovered. Interpretation: Physical frailty and pre-frailty are common following hospitalisation with COVID-19. Improvement in frailty was seen between 5 and 12 months although two-thirds of the population remained pre-frail or frail. This suggests comprehensive assessment and interventions targeting pre-frailty and frailty beyond the initial illness are required. Funding: UK Research and Innovation and National Institute for Health Research